Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.08.2014 | case report

Levosimendan reverses right-heart failure in a 51-year-old patient after heart transplantation

verfasst von: Stjepan Barisin, MD, PhD, Viktor Djuzel, MD, Ana Barisin, MD, PhD, Igor Rudez, MD, PhD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2014

Einloggen, um Zugang zu erhalten

Summary

Primary graft failure in the early postoperative period after heart transplantation, remains a main cause of a poor outcome. Current treatment options include pharmacological (catecholamines and phosphodiesterase inhibitors) and mechanical assist device support. Pharmacological support with catecholamines is related to elevated myocardial oxygen consumption and regional hypoperfusion leading to organ damage. On the other hand, levosimendan, as a calcium-sensitizing agent increases cardiac contractility without altering intracellular Ca2+ levels and increase in oxygen demand.
We present a case of a 51-year-old man, who was suffering from acute right-heart failure in the early postoperative period after heart transplantation. As a rescue therapy at the late stage of a low cardiac output state, levosimendan was started as continuous infusion at 0.1 μg/kg/min for 12 h and thereafter, at 0.2 μg/kg/min for the following 36 h. Levosimendan demonstrated an advanced pharmacological option as was portrayed in this case, where the right ventricle was under a prolonged severe depression and acutely overloaded after heart transplantation.
Vorheriger Artikel Life-threatening heat stroke presenting with ST elevations: a report of consecutive cases during the heat wave in Austria in July 2013
Nächster Artikel BILLROTHHAUS.TV
Literatur
1.
Mitropoulos FA, Odim J, Marelli D, et al. Outcome of hearts with cold ischemic time greater than 300 min. A case-matched study. Eur J Cardiothorac Surg. 2005;28(1):143–8.PubMedCrossRef
2.
Hauer D, Beiras-Fernandez A, Kur F, Weis M, Schmoeckel M, Weis FC. The management of severe primary graft failure after cardiac transplantation. J Cardiothorac Vasc Anesth. 2009;23(2):203–5.PubMedCrossRef
3.
Morais RJ. Levosimendan in severe right ventricular failure following mitral valve replacement. J Cardiothorac Vasc Anesth. 2006;20(1):82–4.PubMedCrossRef
4.
Mebazaa A, Karpati P, Renaud E, Algotsson L. Acute right ventricular failure—from pathophysiology to new treatments. Intensive Care Med. 2004;30(2):185–96.PubMedCrossRef
5.
Beiras-Fernandez A, Weis FC, Fuchs H, Meiser BM, Reichart B, Weis M. Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery? Transplantation. 2006;82(8):1101–3.PubMedCrossRef
6.
Jahania MS, Mullett TW, Sanchez JA, Narayan P, Lasley RD, Mentzer RM Jr. Acute allograft failure in thoracic organ transplantation. J Card Surg. 2000;15(2):122–8.PubMed
7.
Beiras-Fernandez A, Kur F, Kaczmarek I, et al. Levosimendan for primary graft failure after heart transplantation: a 3-year follow-up. Transplant Proc. 2011;43(6):2260–2.PubMedCrossRef
8.
Colucci WS, Wright RF, Jaski BE, Fifer MA, Braunwald E. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation. 1986;73(3):75–83.
9.
Banfor PN, Preusser LC, Campbell TJ, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008;294:238–48.CrossRef
10.
Antila S, Kivikko M, Lehtonen L, et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol. 2004;57(4):412–5.PubMedCentralPubMedCrossRef
11.
Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002;42(1):43–51.PubMedCrossRef
12.
Braun JP, Jasulaitis D, Moshirzadeh M, et al. Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure. Crit Care. 2006;10:569–75.
13.
Lilleberg J, Ylonene V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J. 2004;38(2):80–4.PubMedCrossRef
14.
Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002;40(10):465–71.PubMedCrossRef
15.
Westphal M, Morelli A, Van Aken H. Dear levosimendan. the right ventricle will thank you! Crit Care Med. 2007;35(3):952–3.PubMedCrossRef
16.
Missant C, Rex S, Segers P, Wouters PF. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med. 2007;35(3):707–15.PubMedCrossRef
17.
Puttonen J, Kantele S, Kivikko M, et al. Effect of severe failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet. 2007;46(3):235–46.PubMedCrossRef
18.
Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Cardiac Fail. 2007;13(6):417–21.CrossRef
19.
Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21(6):431–5.PubMedCrossRef
20.
Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology. 2006;104(3):556–69.PubMedCrossRef
Metadaten
Titel
Levosimendan reverses right-heart failure in a 51-year-old patient after heart transplantation
verfasst von
Stjepan Barisin, MD, PhD
Viktor Djuzel, MD
Ana Barisin, MD, PhD
Igor Rudez, MD, PhD
Publikationsdatum
01.08.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0528-2

Weitere Artikel der Ausgabe 15-16/2014

The effect of growth hormone replacement therapy on the morphological and functional changes in the left ventricle in patients with adult-onset growth hormone deficiency

  • original article

The prevalence and clinical importance of incidentally detected noncoronary cardiovascular findings with coronary multidetector CT angiography

  • original article

The association of serum albumin with coronary slow flow

  • original article

BILLROTHHAUS.TV

  • mitteilungen der gesellschaft der ärzte in wien

Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease

  • original article

The 2014 AHA/ACC valve disease guideline: new stages of disease, new treatment options, and a call for earlier intervention

  • Editorial